ACCESS Newswire

New Book Release: 'The Dyslexic Edge' by the Dyslexic Entrepreneur, Jamie Waller, and the Dyslexic Professor, Dr. Helen Taylor

9.9.2024 08:00:00 CEST | ACCESS Newswire | Press release

Share

40% of self-made millionaires and 35% of entrepreneurs are dyslexic

LONDON, UK / ACCESSWIRE / September 9, 2024 / Esteemed entrepreneur Jamie Waller, known as "The Dyslexic Entrepreneur," together with leading dyslexia expert Dr. Helen Taylor, is proud to announce the release of their transformative new book, The Dyslexic Edge. This highly anticipated book, available globally on September 12th, unveils the secrets behind why dyslexic thinkers excel in business and often become self-made millionaires.

The Dyslexic Edge delves into the extraordinary lives of some of the world's most successful dyslexic entrepreneurs, offering a unique perspective on how dyslexia can be a powerful asset in the business world. This book may be the first of its kind-written by dyslexics, for dyslexics, and for anyone looking to harness the advantages of dyslexia to boost their career or entrepreneurial journey.

The book features compelling interviews with 14 influential dyslexics, including:

  • Sir Charles Dunstone, the mastermind behind Carphone Warehouse and Five Guys in the UK.

  • Paul Orfalea, founder of Kinko's and a U.S. print billionaire.

  • Kelly Hoppen, the renowned interior designer to David Beckham.

  • Duncan Bannatyne and Theo Paphitis, both well-known investors and TV personalities from Dragon's Den.

  • Kate Griggs, founder of Made By Dyslexia and an advocate for the dyslexic community.

Sir Richard Branson, arguably the most famous dyslexic entrepreneur, planted the seed during a conversation with Jamie Waller on Necker Island in 2023, and it is now available for pre-order and a few days from release.

One of the most eye-opening aspects of The Dyslexic Edge is its exploration of the statistics: 40% of self-made millionaires and 35% of entrepreneurs are dyslexic. The book addresses a crucial question: What is it about dyslexia that makes dyslexic thinkers great at becoming rich? Jamie Waller and Dr. Helen Taylor uncover these secrets and share them with readers, providing valuable insights into how dyslexic traits such as creative problem-solving, resilience, and innovative thinking contribute to exceptional success.

"By telling these stories, we hope to inspire others with dyslexia to recognise their condition not as a barrier but as a unique strength that can lead to incredible success," said Jamie Waller.

Co-author Dr. Helen Taylor brings her academic expertise to the table, ensuring that the narratives are not only inspiring but also backed by research on the strengths associated with dyslexia.

The Dyslexic Edge is available in all formats and will be sold worldwide, making it accessible to a broad audience eager to learn how dyslexia can be leveraged for extraordinary success.

For more information about the book or to schedule an interview with Jamie Waller or Dr. Helen Taylor, please contact jw@jamiewaller.co.uk or 07779 714 390.

About the Authors:

Jamie Waller is an entrepreneur, author, and advocate known as "The Dyslexic Entrepreneur." He has founded and sold several successful businesses and now dedicates his time to helping others realise their potential, having set up The Prince's Trust Enterprise Network in 2021.

Dr. Helen Taylor is a respected academic specialising in the strengths and advantages of dyslexia. She has published extensively on the topic and is passionate about helping dyslexics leverage their unique abilities.

Contact Information:

Jamie Waller
The Dyslexic Entrepreneur
jw@jamiewaller.co.uk
07779714390

Related Files

Jamie Waller Media

SOURCE: The Dyslexic Entrepreneur

View the original press release on newswire.com.

The Dyslexic Entrepreneur

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States4.2.2026 15:45:00 CET | Press release

Industry recognition for the third consecutive year reinforces AGFA HealthCare's clinician-first commitment, and leadership in empowering connected, high-performance imaging environments MORTSEL, BE / ACCESS Newswire / February 4, 2026 / AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide. The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights. AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinica

Preservica Redefines Digital Preservation with Powerful Built-In AI Tools4.2.2026 15:00:00 CET | Press release

OXFORD, UK and BOSTON, MA / ACCESS Newswire / February 4, 2026 / Preservica, the leader in AI-powered Active Digital Preservation™, today announced the rollout of integrated, human-centered AI tools and flexible AI Credits across its product editions. These new features make AI assistance a seamless part of everyday archival workflows, empowering organizations of all sizes to safely adopt AI and scale its use as their needs grow. "With the sheer volume of digital content in backlogs and being created daily, using AI to assist in archival tasks has now become essential" says Stuart Reed, Chief Product Officer at Preservica "Seamlessly integrating human-centered AI tools across our product editions turns AI for Digital Preservation into reality - enabling organizations of all sizes to accelerate routine work, cut backlogs and enhance discovery." Developed in collaboration with Preservica's user community and refined through the company's highly rated AI Workshop series, these embedded to

Karbon-X Files Quarterly Report on Form 10-Q Highlighting Strong Revenue Growth and Commercial Scale4.2.2026 15:00:00 CET | Press release

CALGARY, AB / ACCESS Newswire / February 4, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the six months ended November 30, 2025. The filing highlights continued momentum in Karbon-X's commercial operations, driven by significant revenue growth and the expansion of its global carbon activities across both compliance and voluntary markets. "Over the past several quarters, we transformed Karbon-X from a developing platform into a scaled, revenue-generating global operator," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "Revenue increased to $56.5 million (USD), compared to $1.3 million (USD) in the prior-year period, reflecting the strength of our commercial strategy and the growing demand for high-integrity carbon solutions. As we continue to invest in scaling our operations, our expanding global footprint, improved profitability, a

Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant4.2.2026 14:00:00 CET | Press release

Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported by a USD 151 million grant) and, simultaneously, a new platform trial for progressive supranuclear palsy (PSP) (supported by a USD 75 million grant) SAN FRANCISCO, CA / ACCESS Newswire / February 4, 2026 / Axon Neuroscience, a global leader in immunotherapy for human neurodegenerative diseases with an internationally recognized scientific team, announces the achievement of two historic milestones with the potential to significantly influence the future treatment of Alzheimer's disease and progressive supranuclear palsy (PSP): 1. AADvac1 Selected as the First Tau Therapy in the Phase 2 Alzheimer's Tau Platform (ATP) Combination-Therapy Trial An independent panel of leading U.S. scientific and clinical experts selected AADvac1 as the first therapy targeting pathological tau protein to be evaluated in

CHAR Technologies Licenses High-Temperature Pyrolysis Technology to GazoTech SAS for Entry Into European Markets4.2.2026 14:00:00 CET | Press release

TORONTO, ON / ACCESS Newswire / February 4, 2026 / CHAR Technologies Ltd. ("CHAR Tech" or "the Company") (TSXV:YES)(FSE:68K) a leader in sustainable biomass energy solutions, today announced that it has entered into a formal technology know-how licensing agreement with GazoTech SAS ("GazoTech"), a France-based energy developer, to support deployment of CHAR Tech's technology in France and selected European markets. The agreement follows recent commissioning progress at CHAR Tech's Thorold Renewable Energy Facility and complements the Company's ongoing development of larger-scale projects in North America. Under the agreement, CHAR Tech is the licensor of its proprietary High-Temperature Pyrolysis ("HTP") technology, granting GazoTech a know-how licence for projects developed in France as well as certain additional European markets, subject to project-by-project application of the licenced technology. GazoTech has multiple projects in development in France, notably: An industrial integr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye